E-ISSN 2231-3206 | ISSN 2320-4672
 

Review Article

Online Publishing Date:
05 / 06 / 2013

 


Newer anti-platelet and anti-thrombotic drugs on the horizon

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi.


Abstract
Aspirin is a highly successful antiplatelet drug & still retains its status as the 'front-line' antiplatelet drug; however, increased understanding of platelet biology has led to the development of new antiplatelet drugs that are potentially more effective. Now, more researches in platelet biology has led to this fact that there are more than 90 other metabolic pathways leading to platelet aggregation that are independent of arachidonic acid and therefore not inhibited by aspirin, hence, several more drugs are being developed, aimed at controlling different phases of platelet function such as platelet aggregation & adhesion. The newer drugs now offer potentially greater and more specific control over platelet function. Definitely, these drugs are going to be significantly more expensive than aspirin, and their eventual role in the clinical arena will ultimately depend on both their efficacy and their cost-effectiveness. As we approach the next millennium, it is envisaged that our increased understanding of platelet function, coupled with advances in technology and drug manufacture, will result in even greater improvements in the therapeutic control of platelet thrombus.

Key words: Prasugrel; Ticagrelor; Antiplatelet Drug Therapy; Pathophysiology of Platelet Aggregation


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Ajai Garg
Articles by Anjana Pandey
Articles by Pranab Oza
Articles by Mridul Chaturvedi
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. 2013; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131


Web Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. https://www.njppp.com/?mno=9978 [Access: March 17, 2024]. doi:10.5455/njppp.2013.3.090420131


AMA (American Medical Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. 2013; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131



Vancouver/ICMJE Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol. (2013), [cited March 17, 2024]; 3(2): 105-110. doi:10.5455/njppp.2013.3.090420131



Harvard Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi (2013) Newer anti-platelet and anti-thrombotic drugs on the horizon. Natl J Physiol Pharm Pharmacol, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131



Turabian Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. 2013. Newer anti-platelet and anti-thrombotic drugs on the horizon. National Journal of Physiology, Pharmacy and Pharmacology, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131



Chicago Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. "Newer anti-platelet and anti-thrombotic drugs on the horizon." National Journal of Physiology, Pharmacy and Pharmacology 3 (2013), 105-110. doi:10.5455/njppp.2013.3.090420131



MLA (The Modern Language Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi. "Newer anti-platelet and anti-thrombotic drugs on the horizon." National Journal of Physiology, Pharmacy and Pharmacology 3.2 (2013), 105-110. Print. doi:10.5455/njppp.2013.3.090420131



APA (American Psychological Association) Style

Ajai Garg, Anjana Pandey, Pranab Oza, Mridul Chaturvedi (2013) Newer anti-platelet and anti-thrombotic drugs on the horizon. National Journal of Physiology, Pharmacy and Pharmacology, 3 (2), 105-110. doi:10.5455/njppp.2013.3.090420131